-
EMA Gives Preterm Preeclampsia Treatment Orphan Drug Designation
08 Apr 2025 23:29 GMT
… each year. A novel siRNA drug candidate, CBP-4888 is … placenta. Currently an investigational drug candidate, CBP-4888 has … EMA grants orphan drug designation to drugs and biologics intended … Sponsors who obtain orphan drug designation benefit from protocol …
-
Novel Drug Moving Forward for Lp(a)
08 Apr 2025 21:12 GMT
… , where the effect of the siRNA is to degrade messenger RNA … trial, which will test the drug';s ability to prevent … for elevated Lp(a), a genetically mediated risk factor, ACCLAIM-Lp …
-
7 Analysts Assess Voyager Therapeutics: What You Need To Know
08 Apr 2025 20:31 GMT
… recent developments related to Voyager Therapeutics. This information provides a … it here.
About Voyager Therapeutics
Voyager Therapeutics Inc is a gene therapy … (siRNA), FXN Gene Therapy among others.
Understanding the Numbers: Voyager Therapeutics…
-
Atalanta Therapeutics Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related Epilepsy
08 Apr 2025 12:14 GMT
… submit an Investigational New Drug (IND) application to … preclinical model of KCNT1 genetic epilepsy with divalent …
About Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company developing … small interfering RNA (di-siRNA) is designed to …
-
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
08 Apr 2025 11:00 GMT
… each year. A novel siRNA drug candidate, CBP-4888 is … EMA grants orphan drug designation to drugs and biologics intended for … Sponsors who obtain orphan drug designation benefit from protocol … CBP-4888, an innovative siRNA therapeutic candidate that, if …
-
The New Drug Talk Oregon offers new ways to have important conversations
07 Apr 2025 16:43 GMT
… drug landscape. The New Drug Talk Oregon’s Jennifer Epstein joined Natalie Sirna … and then came The New Drug Talk Oregon. Epstein’s … more about fentanyl and other drugs, counterfeit pills, and ways … resources, visit The New Drug Talk Oregon’s website. …
-
This cholesterol type is a heart risk. New Lilly and Amgen drugs could treat it.
07 Apr 2025 12:18 GMT
… genetic. So lifestyle doesn’t much affect it. Neither can available drugs … based biotech Silence Therapeutics is developing its lipoprotein(a) drug solo. … interfering RNA", or siRNA—which degrade the RNA. … first of these Big Pharma companies with an answer. …
-
ABL Bio spikes 30% on $2.7 bil. GSK licensing deal for BBB-shuttling brain drugs
07 Apr 2025 07:03 GMT
… 73 billion) with British pharma giant GSK to develop brain … morning, after the Korean biotech disclosed the pact—its … antibodies, small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and … toughest technical problems: getting drugs past the BBB. …
-
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
06 Apr 2025 14:20 GMT
… ventilators and heart failure drugs alone.
Investment Outlook … Historical and Projected: Capricor Therapeutics (NASDAQ: CAPR) has … invaluable for treating genetic disorders or diseases … new collaborations with biotech or Pharma companies specializing in …
-
MiR-148a-3p Loaded Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Alleviates Silica-Induced Pulmonary Fibrosis by Inhibiting β-Catenin Signaling
08 Apr 2025 15:04 GMT
… interfering RNA (siRNA) targeting Hsp90b1 (siHsp90b1) (Sangong Biotech Co., Ltd., … in the preparation of drugs for silicosis treatment … as a next-generation drug delivery platform. Nat Nanotechnol … of miRNA therapeutics: from cells to clinic. Trends Genet. 2022 …
About
© 1995-2025